HK1123055A1 - Hepatitis c virus nucleic acid vaccine - Google Patents

Hepatitis c virus nucleic acid vaccine

Info

Publication number
HK1123055A1
HK1123055A1 HK08114140.2A HK08114140A HK1123055A1 HK 1123055 A1 HK1123055 A1 HK 1123055A1 HK 08114140 A HK08114140 A HK 08114140A HK 1123055 A1 HK1123055 A1 HK 1123055A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
nucleic acid
acid vaccine
virus nucleic
virus
Prior art date
Application number
HK08114140.2A
Other languages
English (en)
Inventor
Armin Lahm
Stefano Colloca
Antonella Folgori
Alfredo Nicosia
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of HK1123055A1 publication Critical patent/HK1123055A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK08114140.2A 2005-06-17 2008-12-31 Hepatitis c virus nucleic acid vaccine HK1123055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69152305P 2005-06-17 2005-06-17
US69951405P 2005-07-15 2005-07-15
PCT/EP2006/005697 WO2006133911A2 (en) 2005-06-17 2006-06-13 Hepatitis c virus nucleic acid vaccine

Publications (1)

Publication Number Publication Date
HK1123055A1 true HK1123055A1 (en) 2009-06-05

Family

ID=37074602

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08114140.2A HK1123055A1 (en) 2005-06-17 2008-12-31 Hepatitis c virus nucleic acid vaccine

Country Status (9)

Country Link
US (1) US9056090B2 (xx)
EP (2) EP1893636A2 (xx)
JP (1) JP5475279B2 (xx)
CN (1) CN101213204B (xx)
AU (1) AU2006257323B2 (xx)
CA (1) CA2610919C (xx)
ES (1) ES2948791T3 (xx)
HK (1) HK1123055A1 (xx)
WO (1) WO2006133911A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1893636A2 (en) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
WO2009079834A1 (fr) * 2007-12-18 2009-07-02 Peking University People's Hospital Vaccin anti-vhc et procédés de préparation et utilisations de celui-ci
US8470310B2 (en) 2008-03-04 2013-06-25 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
JP5753090B2 (ja) 2008-10-29 2015-07-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良型ｈｃｖワクチンおよびその使用方法
BRPI1008018A2 (pt) 2009-02-02 2016-03-15 Okairos Ag ácidos nucleicos de adenovírus símio e sequências de aminoácidos, vetores contendo os mesmos e uso dos mesmos
TR201902214T4 (tr) * 2010-04-16 2019-03-21 Glaxosmithkline Biologicals Sa Şempanze adenoviral vektörü-bazlı filovirüs aşıları.
KR101913674B1 (ko) * 2011-10-24 2018-10-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 hcv 백신 및 이것을 사용하는 방법
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
AU2016275619B2 (en) * 2015-06-12 2019-09-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CA3013639A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN116802280B (zh) * 2021-01-21 2024-09-17 希力德株式会社 不包括有复制能力的腺病毒的新型腺病毒载体及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
DE3584341D1 (de) * 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5266313A (en) 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5989245A (en) 1994-03-21 1999-11-23 Prescott; Marvin A. Method and apparatus for therapeutic laser treatment
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DK0833934T4 (da) * 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
ATE311463T1 (de) * 1996-05-24 2005-12-15 Chiron Corp Fusionsprotein mit multiplen epitopen
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
EP1009763A4 (en) 1996-06-11 2002-08-07 Merck & Co Inc SYNTHETIC GENES OF HEPATITIS C
FR2761689B1 (fr) * 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
DE69835761T2 (de) 1997-04-03 2007-09-13 Electrofect As. Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
CN1246922A (zh) 1997-12-09 2000-03-08 松下电器产业株式会社 旋光度测定装置和尿检查方法
JP2002511396A (ja) 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド ポリヌクレオチド製剤の無針投与
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6156588A (en) 1998-06-23 2000-12-05 Vlsi Technology, Inc. Method of forming anti-fuse structure
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
CA2390082C (en) 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
ATE530672T1 (de) * 2001-06-22 2011-11-15 Univ Pennsylvania Rekombinante adenoviren mit affen-adenovirus proteinen und verwendung davon.
DK1436397T3 (da) * 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine
EP1539937A4 (en) 2002-08-22 2006-07-26 Merck & Co Inc METHODS OF PROPAGATION OF ADENOVIRUS AND VIRUS SO OBTAINED
WO2004099422A2 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
TWI291500B (en) 2003-05-07 2007-12-21 Univ Southern California Method of electrochemically fabricating multilayer structures having improved interlayer adhesion
EP1711518B1 (en) 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Chimpanzee adenovirus vaccine carriers
EP1893636A2 (en) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine

Also Published As

Publication number Publication date
US20090035277A1 (en) 2009-02-05
US9056090B2 (en) 2015-06-16
EP2570423A1 (en) 2013-03-20
JP2008543295A (ja) 2008-12-04
EP1893636A2 (en) 2008-03-05
EP2570423B1 (en) 2023-05-03
WO2006133911A2 (en) 2006-12-21
CN101213204A (zh) 2008-07-02
AU2006257323A1 (en) 2006-12-21
CN101213204B (zh) 2013-06-19
ES2948791T3 (es) 2023-09-19
CA2610919C (en) 2013-09-10
WO2006133911A3 (en) 2007-04-12
AU2006257323B2 (en) 2011-12-22
JP5475279B2 (ja) 2014-04-16
CA2610919A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
HK1123055A1 (en) Hepatitis c virus nucleic acid vaccine
HRP20160410T8 (hr) Inhibitori hepatitis c virusa
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
AP2907A (en) Viral hepatitis treatment
IL194920A0 (en) Hepatitis c virus infection biomarkers
DK1858917T3 (da) Varicella-zoster-virus-vaccine
HK1144440A1 (en) Hepatitis c virus antibodies
HK1138297A1 (en) Human antibodies against hepatitis c virus (hcv) uses thereof (hcv)
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
IL189329A0 (en) Vaccination against dengue virus infection
HK1223968A1 (zh) 狂犬病病毒組合物和方法
ZA200809056B (en) Influenza virus vaccine
EP1871411A4 (en) EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
EP1856250A4 (en) NEW VACCINES LIVING VIRUSES
EP2205617A4 (en) SPECIFIC OLIGONUCLEOTIDE SEQUENCES OF HEPATITIS B VIRUS (HBV)
HK1109069A1 (en) Vaccine composition against hepatitis c virus
EP1871786A4 (en) PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS
ZA200709605B (en) HIV vaccine
ZA200802176B (en) Vaccination against dengue virus infection
EP2004685A4 (en) HEPATITIS C VIRUS NEUTRALIZING ANTIBODIES
ZA200804099B (en) Multiclade HIV vaccines
GB0508061D0 (en) RNA viruses
GB0508060D0 (en) RNA viruses
GB0501582D0 (en) Hepatitis c virus replication system
GB0517835D0 (en) DNA viral infections